Novo Nordisk A/S: Alhemo® recommended for European approval as first once-daily subcutaneous prophylactic treatment for people living with haemophilia A or B with inhibitors
October 18, 2024 05:32 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 18 October 2024 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion,...
Novo Nordisk A/S - share repurchase programme
October 14, 2024 08:06 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 14 October 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...
Novo Nordisk launches new initiative to prevent childhood obesity in disadvantaged urban communities
October 08, 2024 04:00 ET
|
Novo Nordisk A/S
The initiative will launch in six cities across five continentsInterventions aim to increase physical activity and healthy eating among childrenThe three-year initiative comes with an investment of...
Novo Nordisk A/S – Share repurchase programme
October 07, 2024 06:44 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 7 October 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...
Novo Nordisk A/S – Share repurchase programme
September 30, 2024 07:02 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 30 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
Novo Nordisk A/S - share repurchase programme
September 23, 2024 07:56 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 23 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed
September 20, 2024 08:43 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse...
Novo Nordisk A/S: Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function
September 19, 2024 15:10 ET
|
Novo Nordisk A/S
Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function Wegovy® (semaglutide 2.4 mg) is the first...
Novo Nordisk A/S - share repurchase programme
September 16, 2024 09:15 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 16 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
Novo Nordisk A/S - share repurchase programme
September 09, 2024 10:10 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 9 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...